Document is current
Any future updates will be listed below
-
Authors
Wilcox-King, Andrew
Wan, Yu-Hsin
Scharffenberger, Samuel C.
Chhan, Crystal B.
Davis, Amelia R.
Homad, Leah J.
Seydoux, Emilie
MacPhee, Kellie J.
Siddaramaiah, Latha Kallur
Melo, Mariane
Dosenovic, Pia
Irvine, Darrell J.
Hyrien, Ollivier
Stamatatos, Leonidas
McGuire, Andrew T.
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (P01AI138212, P01AI138212, P01AI138212, P01AI138212, P01AI138212, P01AI138212, P01AI138212, P01AI138212, P01AI138212, P01AI138212, UM1AI144462, P01AI138212, P01AI138212)
Bill and Melinda Gates Foundation (INV-032929, INV-032929)
- License Information
-
More Information
Article History
Received: 6 February 2025
Accepted: 14 July 2025
First Online: 5 August 2025
Competing interests
: L.S. and A.T.M. are inventors on the following patents and applications related to the 426c.Mod.Core protein used herein: US patent #10,342,863—Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof, US patent #10,987,417—Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof, US patent #11,883,485—Methods of eliciting antibodies that bind to full-length glycosylated HIV-1 ENV using multimerized ENV cores, and US patent #18/402,480 (pending)—Sequential immunization strategies to guide the maturation of antibodies against human immunodeficiency virus. DJI is named as an inventor on a patent for SMNP: US patent #11,547,672—Nanoparticle vaccine adjuvant and methods of use thereof. All other authors declare no competing interests.
